Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Tyrosine kinase Stories

2013-12-05 08:29:12

SAN DIEGO, Dec. 5, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Oppenheimer 24(th) Annual Healthcare Conference to be held at the Crown Plaza Hotel in New York City, December 10-11, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug...

2013-11-19 23:03:33

Reportbuyer.com just published a new market research report: Orphan Drugs in Oncology Drug Pipeline Update 2013. London (PRWEB) November 19, 2013 This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation...

2013-11-01 16:23:39

SAN DIEGO, Calif., Nov. 1, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report third quarter 2013 operational results after closing of the NASDAQ Global Market on Thursday, November 7, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update...

2013-10-17 08:22:50

Stivarga(®) (regorafenib tablets) receives expanded approval to include Gastrointestinal Stromal Tumours (GIST) after being approved for metastatic colorectal cancer earlier this year TORONTO, Oct. 17, 2013 /CNW/ - Bayer Inc. announced today Health Canada's expanded approval of Stivarga(®) (regorafenib tablets) to now include treatment of adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) who have had disease progression on or intolerance...

2013-09-19 08:28:11

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013. Michael Martino, Ambit's CEO, will provide an overview of the Company and its...

2013-08-29 12:26:37

After identifying a protein that blocks death of high-risk acute lymphoblastic leukemia (ALL) cells, scientists use two-drug combination therapy to offer hope to children and adults with the disease MEMPHIS, Tenn., Aug. 29, 2013 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital scientists have identified a protein that certain high-risk acute lymphoblastic leukemia (ALL) cells need to survive and have used that knowledge to fashion a more effective method of killing...

2013-08-06 16:28:45

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report second quarter 2013 operational results after closing of the NASDAQ Global Market on August 13, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update at 5 p.m. EDT (2...

2013-07-29 08:25:39

ROCKVILLE, Md., July 29, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today that it has initiated a crossover bioavailability and food effect study of ENMD-2076. The study is a single-blind, randomized, single-dose, crossover study with a food effect arm to investigate the safety and relative bioavailability of two dosage forms of ENMD-2076 administered as...

2013-07-03 16:22:44

SAN DIEGO, July 3, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at the 8(th) Annual JMP Securities Healthcare Conference. Mr. Martino's presentation is scheduled to take place at 9:30 a.m. EDT on Wednesday, July 10, at the St. Regis New York. A live webcast of the presentation will be accessible in the investors section of the company's website, www.ambitbio.com,...

2013-06-20 23:34:37

Latest results of Phase 2 study confirm high rate of response, remission In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL). The most recent interim findings of the 18-center Phase 2 study were published today in the New England Journal of Medicine. Previous interim findings were presented in...